Susquehanna Fundamental Investments’s Crescent Biopharma CBIO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$104K	Hold	909	–	–	﹤0.01%	1447
2021 Q4	$131K	Sell	909 -448	-33%	-$81.3K	﹤0.01%	1307
2021 Q3	$297K	Sell	1,357 -90	-6%	-$19.1K	0.01%	1412
2021 Q2	$336K	Buy	1,447 +1,054	+268%	+$268K	0.01%	1324
2021 Q1	$118K	Sell	393 -257	-40%	-$92K	﹤0.01%	1451
2020 Q4	$244K	Sell	650 -289	-31%	-$101K	﹤0.01%	1314
2020 Q3	$288K	Buy	939 +833	+786%	+$318K	0.01%	1077
2020 Q2	$40K	Buy	+106	New	+$30K	﹤0.01%	947

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna Fundamental Investments's CBIO Position: Q1 2022 in Review

Susquehanna Fundamental Investments held its Crescent Biopharma (CBIO) position steady in Q1 2022 at 909 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #1447.

Susquehanna Fundamental Investments first reported a position in CBIO in Q2 2020 and has held it in 8 quarters since. The position peaked at $336K in Q2 2021. 43 funds tracked by Wall St. Rank hold CBIO as of Q1 2022.

Susquehanna Fundamental Investments held 909 shares of Crescent Biopharma worth $104K as of Q1 2022.
Susquehanna Fundamental Investments left its Crescent Biopharma share count unchanged in Q1 2022.
Crescent Biopharma made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1447 holding.
Susquehanna Fundamental Investments first reported a position in Crescent Biopharma in Q2 2020 and has held it in 8 quarters since.
Susquehanna Fundamental Investments's Crescent Biopharma position peaked at $336K in Q2 2021.
43 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.